PMID- 32647562 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231111 IS - 2042-0188 (Print) IS - 2042-0196 (Electronic) IS - 2042-0188 (Linking) VI - 11 DP - 2020 TI - Suboptimal glycemic control among subjects with diabetes mellitus in India: a subset analysis of cross-sectional wave-7 (2016) data from the International Diabetes Management Practices Study (IDMPS). PG - 2042018820937217 LID - 10.1177/2042018820937217 [doi] LID - 2042018820937217 AB - OBJECTIVE: To assess the real-world management practices of subjects with type 2 diabetes mellitus (T2DM) and type 1 diabetes mellitus (T1DM) in India. METHODS: This cross-sectional study was conducted between 7 March 2016 and 15 May 2016 in India as part of the seventh wave (2016) of the International Diabetes Management Practices Study (IDMPS). Adult subjects with T1DM or T2DM visiting physicians during a 2-week recruitment period were included. RESULTS: A total of 55 physicians included 539 subjects who met eligibility criteria. Of 495 subjects with T2DM, 303 were treated with oral glucose lowering drugs (OGLDs) only, 158 were treated with OGLD + insulin, and 27 received insulin only. Among 44 subjects with T1DM receiving insulin, 13 (29.5%) were also treated with OGLD therapy. The most commonly used insulin regimens were basal alone (69/184; 37.5%) and premixed alone (63/184; 34.2%) in subjects with T2DM, and basal + prandial insulin (24/44; 54.5%) in subjects with T1DM. Proportions of subjects achieving glycemic targets were low [glycated haemoglobin (HbA1c) <7%: T1DM = 7.3% (3/44), T2DM = 25.2% (106/495); as targeted by the treating physician: T1DM = 31.8% (14/44), T2DM = 32.1% (59/185); global target: T1DM = 4.8% (2/42) and T2DM = 1.7% (8/482)]. In subjects with T2DM, HbA1c <7% was noted in 11/22 subjects receiving insulin only and 76/260 receiving only OGLDs. Lack of experience in self-managing insulin dosing, poor diabetes education and failure to titrate insulin dosages were the main reasons for non-achievement of glycemic targets. CONCLUSION: Timely insulinization, education and empowerment of people with diabetes may help improve glycemic control in India. CI - (c) The Author(s), 2020. FAU - Ramachandran, Ambady AU - Ramachandran A AUID- ORCID: 0000-0002-2771-6290 AD - Department of Diabetology, Dr. Ramachandran's Diabetes Hospital, No. 28, Marshall's Road, Egmore, Chennai 600 008, India. FAU - Jain, Sunil M AU - Jain SM AD - Department of Endocrinology, TOTALL Diabetes Hormone Institute, Indore, India. FAU - Mukherjee, Sagarika AU - Mukherjee S AD - Department of Diabetology, Dr. Sagarika Mukherjee's Endocrinology Clinic, Kolkata, India. FAU - Phatak, Sanjeev AU - Phatak S AD - Department of Diabetology, Vijayratna Diabetes Diagnosis and Treatment Centre, Ahmedabad, India. FAU - Pitale, Shailesh AU - Pitale S AD - Department of Diabetology, Pitale Diabetes and Hormone Centre, Nagpur, India. FAU - Singh, Shailendra K AU - Singh SK AD - Department of Diabetology, Dr. Shailendra Kumar Singh's Clinic, Varanasi, India. FAU - Agrawal, Navneet AU - Agrawal N AD - Department of Diabetology and Obesity, Diabetes, Obesity and Thyroid Centre, Gwalior, India. FAU - Majumdar, Anirban AU - Majumdar A AD - Department of Endocrinology, Anirban's Diabetes- Obesity-Thyroid & Hormone Clinic, Kolkata, India. FAU - Deshpande, Neeta AU - Deshpande N AD - Department of Diabetology, Belgaum Diabetes Centre, Belgaum. FAU - Jhulka, Sandeep AU - Jhulka S AD - Department of Diabetology, Radiance the Hormone Health Clinic, Indore, India. FAU - Minakshisundaram, Shunmugavelu AU - Minakshisundaram S AD - Department of Diabetology, Trichy Diabetes Speciality Centre (P) Ltd., Trichy, India. FAU - Chawla, Manoj AU - Chawla M AD - Department of Diabetology, Lina Diabetes Care Centre and Mumbai Diabetes Research Centre, Mumbai, India. FAU - Lodha, Sailesh AU - Lodha S AD - Department of Endocrinology, Dr. Sailesh Lodha Clinic, Rajasthan, India. FAU - Maheshwari, Anuj AU - Maheshwari A AD - Department of Diabetology, Shri Hari Kamal Diabetes and Research Clinic, Lucknow, India. FAU - Makkar, Brij Mohan AU - Makkar BM AD - Department of Diabetology and Obesity, Diabetes and Obesity Centre, New Delhi, India. FAU - Rao, Sadashiva AU - Rao S AD - Department of Diabetology, Diabetic Care Centre, Vijayawada, India. FAU - Shah, Parag AU - Shah P AD - Department of Endocrinology, Gujarat Endocrine Centre, Ahmedabad, India. FAU - Ghosh, Romik AU - Ghosh R AD - Medical Affairs, Sanofi India Limited, Mumbai, Maharashtra, India. FAU - Mohanasundaram, Senthilnathan AU - Mohanasundaram S AD - Medical Affairs, Sanofi India Limited, Mumbai, Maharashtra, India. FAU - Menon, Shalini AU - Menon S AD - Medical Affairs, Sanofi India Limited, Mumbai, Maharashtra, India. FAU - Chodankar, Deepa AU - Chodankar D AD - Clinical Study Unit, Sanofi Synthelabo India Limited, Mumbai, Maharashtra, India. FAU - Kanade, Vaishali AU - Kanade V AD - Clinical Study Unit, Sanofi Synthelabo India Limited, Mumbai, Maharashtra, India. FAU - Trivedi, Chirag AU - Trivedi C AD - Clinical Study Unit, Sanofi Synthelabo India Limited, Mumbai, Maharashtra, India. LA - eng PT - Journal Article DEP - 20200627 PL - United States TA - Ther Adv Endocrinol Metab JT - Therapeutic advances in endocrinology and metabolism JID - 101532143 PMC - PMC7325532 OTO - NOTNLM OT - Glycated haemoglobin OT - IDMPS OT - type 1 diabetes mellitus OT - type 2 diabetes mellitus COIS- Conflict of interest statement: Shunmugavelu Minakshisundaram was a study investigator and received an honorarium during the period in which the study was conducted. Anirban Majumdar is a consultant and/or speaker for Eli Lilly, Novo Nordisk India, Sanofi India Limited, and Wockhardt India Ltd. that market different insulin preparations. MC is a member of the speaker bureau for Sanofi, Eli Lilly, Novo Nordisk, Boehringer Ingelheim, AstraZeneca, USV, IPCA, Biocon, and Cipla. SMJ has been associated with Sanofi, Novo, Eli Lilly, Novartis, Boehringer-Ingelheim, and AstraZeneca for various trials and educational initiatives. AR, Sagarika Mukherjee, Sanjeev Phatak, Shailesh Pitale, NA, ND, SJ, SL, Anuj Maheshwari, BMM, SR, PS, and SKS declared no conflict of interest. RG, Senthilnathan Mohanasundaram, Shalini Menon, DC, VK, CT are employees of Sanofi. EDAT- 2020/07/11 06:00 MHDA- 2020/07/11 06:01 PMCR- 2020/06/27 CRDT- 2020/07/11 06:00 PHST- 2019/10/24 00:00 [received] PHST- 2020/05/03 00:00 [accepted] PHST- 2020/07/11 06:00 [entrez] PHST- 2020/07/11 06:00 [pubmed] PHST- 2020/07/11 06:01 [medline] PHST- 2020/06/27 00:00 [pmc-release] AID - 10.1177_2042018820937217 [pii] AID - 10.1177/2042018820937217 [doi] PST - epublish SO - Ther Adv Endocrinol Metab. 2020 Jun 27;11:2042018820937217. doi: 10.1177/2042018820937217. eCollection 2020.